NEOGAP Therapeutics AB
Andrea Salmén has a diverse work experience in the biotechnology and pharmaceutical industry. Andrea currently holds the position of Chief Operating Officer at NEOGAP Therapeutics AB since April 2022. Prior to that, they served as a Project Leader at both NEOGAP Therapeutics AB and TCER AB from February 2020 to April 2022. Andrea also worked as a Senior Advisor Pharmaceutical Development Biologics at Scandinavian Development Services from September 2018 to February 2020. Earlier in their career, they held the role of Project Manager at Cobra Biologics from 2011 to September 2018. Andrea started their career as a Scientist at Recipharm Biologics AB from January 2009 and later worked as a Research Scientist at AstraZeneca from April 2006 to December 2008.
Andrea Salmén obtained their MSc in Biotechnology from Linköping University from 2001 to 2006.
This person is not in any offices
NEOGAP Therapeutics AB
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.